Cyclerion Therapeutics Statistics
Total Valuation
CYCN has a market cap or net worth of $12.85 million. The enterprise value is $9.57 million.
Important Dates
The next estimated earnings date is Friday, May 8, 2026, after market close.
| Earnings Date | May 8, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
CYCN has 4.23 million shares outstanding. The number of shares has increased by 26.33% in one year.
| Current Share Class | 4.23M |
| Shares Outstanding | 4.23M |
| Shares Change (YoY) | +26.33% |
| Shares Change (QoQ) | +18.17% |
| Owned by Insiders (%) | 17.41% |
| Owned by Institutions (%) | 18.57% |
| Float | 3.49M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.17 |
| Forward PS | n/a |
| PB Ratio | 1.23 |
| P/TBV Ratio | 1.41 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 4.61 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.15
| Current Ratio | 5.15 |
| Quick Ratio | 4.71 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -39.34% and return on invested capital (ROIC) is -34.66%.
| Return on Equity (ROE) | -39.34% |
| Return on Assets (ROA) | -31.78% |
| Return on Invested Capital (ROIC) | -34.66% |
| Return on Capital Employed (ROCE) | -54.74% |
| Weighted Average Cost of Capital (WACC) | 9.15% |
| Revenue Per Employee | $2.07M |
| Profits Per Employee | -$3.53M |
| Employee Count | 1 |
| Asset Turnover | 0.21 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.46% in the last 52 weeks. The beta is 0.89, so CYCN's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | -6.46% |
| 50-Day Moving Average | 2.19 |
| 200-Day Moving Average | 2.07 |
| Relative Strength Index (RSI) | 54.07 |
| Average Volume (20 Days) | 13,848,251 |
Short Selling Information
The latest short interest is 267,352, so 6.33% of the outstanding shares have been sold short.
| Short Interest | 267,352 |
| Short Previous Month | 113,448 |
| Short % of Shares Out | 6.33% |
| Short % of Float | 7.66% |
| Short Ratio (days to cover) | 0.02 |
Income Statement
In the last 12 months, CYCN had revenue of $2.07 million and -$3.53 million in losses. Loss per share was -$1.11.
| Revenue | 2.07M |
| Gross Profit | 1.12M |
| Operating Income | -4.97M |
| Pretax Income | -3.53M |
| Net Income | -3.53M |
| EBITDA | n/a |
| EBIT | -4.97M |
| Loss Per Share | -$1.11 |
Full Income StatementBalance Sheet
The company has $3.24 million in cash and n/a in debt, giving a net cash position of $3.24 million or $0.77 per share.
| Cash & Cash Equivalents | 3.24M |
| Total Debt | n/a |
| Net Cash | 3.24M |
| Net Cash Per Share | $0.77 |
| Equity (Book Value) | 9.09M |
| Book Value Per Share | 2.38 |
| Working Capital | 3.74M |
Full Balance SheetCash Flow
| Operating Cash Flow | -3.31M |
| Capital Expenditures | n/a |
| Depreciation & Amortization | n/a |
| Net Borrowing | n/a |
| Free Cash Flow | -3.31M |
| FCF Per Share | -$0.78 |
Full Cash Flow StatementMargins
Gross margin is 53.76%, with operating and profit margins of -239.78% and -170.11%.
| Gross Margin | 53.76% |
| Operating Margin | -239.78% |
| Pretax Margin | -170.11% |
| Profit Margin | -170.11% |
| EBITDA Margin | n/a |
| EBIT Margin | -239.78% |
| FCF Margin | n/a |